Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10864 | 0.92 | CXCR2 (0.44) | CXCR2ALDH1A1HPGDTSHRCYP4F2 | |
| SCHEMBL30015929 | 0.92 | CXCR2 (0.44) | CXCR2ALDH1A1HPGDTSHRCYP4F2 | |
| SCHEMBL14656987 | 0.83 | KDM4E (0.42) | CXCR2ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL29973532 | 0.83 | KDM4E (0.42) | CXCR2ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL29107963 | 0.81 | CYSLTR2 (0.44) | CXCR2MAPTSMN1; SMN2 | |
| SCHEMBL17939913 | 0.80 | CXCR2 (0.40) | CXCR2ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL28582570 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HPGDMAPTTSHRCYP4F2 | |
| SCHEMBL902458 | 0.79 | LIPG (0.49) | CXCR2ALDH1A1MAPTPOLBTHRB | |
| SCHEMBL12215762 | 0.79 | CYP4F2 (0.56) | CXCR2ALDH1A1MAPTCYP4F2CYP4A11 | |
| SCHEMBL29457774 | 0.79 | CXCR2 (0.40) | CXCR2ROCK1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023232966-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-12-07 | — | — | WO | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OXFORD FINANCE LLC | 2023-10-19 | — | — | US | disclosed |
| CN-116635393-A | Heterocyclic derivatives substituted with a middle or macrocyclic benzyl group and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4208465-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022051583-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331720-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | HCRTR2, HCRTR1, CRHR2 | CXCR2 495/4885ALDH1A1 4091/4885HPGD 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.